Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-09-22
2010-11-09
McGarry, Sean R (Department: 1635)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120, C435S375000, C536S023100, C536S024100, C536S024500
Reexamination Certificate
active
07829547
ABSTRACT:
In a first aspect thereof, the present invention provides a method for treatment and/or prevention of a disease selected from the group consisting of psoriasis and squamous cell carcinoma by inhibiting the expression of squamous cell carcinoma antigen (SCCA) by cells. In another aspect thereof, the present invention provides a method for screening for substances that inhibit epidermal parakeratosis, wherein the activity of a candidate substance that inhibits cysteine protease inhibitory activity possessed by squamous cell carcinoma antigen 1 (SCCA-1) is used as an indicator.
REFERENCES:
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0215509 (2005-09-01), Katagirl et al.
patent: WO 03/100059 (2003-12-01), None
patent: WO 2004/072284 (2004-08-01), None
Suminami et al., Cancer Research vol. 61:1776-1780, 2001.
Katagiri et al., Increased expression of squamous cell carcinoma antigen protects keratinocytes from UVinduced cell death: critical role of SCCA as a natural inhibitor of the stress kinase JNK/SAPK.J. Invest. Dermatol. 122(3), A70, Abstract 417 (2004).
Takeda, A. et al., “Overexpression of Serpin Squamous Cell Carcinoma Antigens in Psoriatic Skin,”Journal of Investigative Dermatology, Jan. 2002, pp. 147-154, vol. 118, No. 1.
Suminami, Y., et al., “Suppression of a Squamous Cell Carcinoma (SCC)- related Serpin, SCC Antigen, Inhibits Tumor Growth with Increased Intratumor Infiltration of Natural Killer Cells,”Cancer Research, Mar. 1, 2001, pp. 1776-1780, 61(5).
Suminami, Y., “Tumor-associated ov-serpin, SCC Antigen, is involved in apoptosis,”Bulletin Yamaguchi Medical School, 2001, pp. 25-27, vol. 48, No. 3-4.
Hamanaka, S., et al., “Serum Level of Squamous Cell Carcinoma Antigen as a New Indicator of Disease Activity in Patients with Psoriasis,”Archives of Dermatology, Mar. 1997, pp. 393-395, vol. 133, No. 3.
Experimental Medicine18(12):172-180 (2000) (Abstract only), Ohtsu et al.
Supplementary European Search Report mailed Apr. 26, 2010, in EP 05787935.5, 4 pages.
Greaves et al., “Treatment of Psoriasis,” New England Journal of Medicine, Mar. 2, 1995, 332(9):581-588.
Katagiri et al., “Novel UV protection mechanism in human skin: role of SCCA in UV-induced cell death,” Journal of Dermatological Science, Apr. 2004, 34(2):126, abstract 044.
Katagiri et al., “Serpin squamous cell carcinoma antigen inhibits UV-induced apoptosis via suppression of c-JUN NH2-terminal kinase,” Journal of Cell Biology, Mar. 2006, 172(7):983-990.
White et al., “Antisense oligonucleotide treatments for psoriasis,” Expert Opinion on Biological Therapy, Jan. 1, 2004, 4(1):75-81.
Wraight et al., “Reversal of epidermal hyperproliferation in psoriasis by insulin-like growth factor I receptor antisense oligonucleotides,” Nature Biotechnology, May 2000, 18(5):521-526.
Experimental Medicine18(12):172-180 (2000) (Abstract only) Ohtsu et al.
Katagiri et al., Increased expression of squamous cell carcinoma antigen protects keratinocytes from UVinduced cell death: critical role of SCCA as a natural inhibitor of the stress kinase JNK/SAPK.J. Invest. Dermatol. 122(3), A70, Abstract 417 (2004).
Hibino Toshihiko
Katagiri Chika
Nakanishi Jotaro
Foley & Lardner LLP
McGarry Sean R
Shiseido Company Ltd.
LandOfFree
Method and pharmaceutical composition for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and pharmaceutical composition for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and pharmaceutical composition for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4200755